EUVIMEDEUVIMED entdecken
Crossref

Upfront allogeneic hematopoietic stem cell transplantation for adult T-cell acute lymphoblastic leukemia/lymphoma in first complete remission: a single-center study

Zhenyang Gu, Fei Li, Meng Li, Lu Wang, Ning Lu, Xiangshu Jin, Lili Wang, Chunji Gao, Liping Dou, Daihong Liu

Annals of Hematology · 2024-07 · 103 (7) · 2445-2454

DOI: 10.1007/s00277-024-05716-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 12.04.2024. Verfasst von Zhenyang Gu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, East St 8th, Fengtai District, Beijing, 100071, China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Remission Induction. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Youth Fund of the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Real-world data on outcomes of upfront allogeneic hematopoietic stem cell transplantation (allo-HCT) for adult T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) patients in first complete remission (CR1) is still lacking. METHODS: A single center retrospective study was conducted from 94 consecutive patients received their first allo-HCT between 2010 and 2021, which include 76 patients received upfront allo-HCT and 18 patients received allo-HCT in non-upfront settings. RESULTS: There were no significant differences in most variables. In the upfront allo-HCT group, 52 (68%) patients achieved CR1 with one cycle of induction regimen. 24 (32%) patients achieved CR1 with more than one cycle. In the non-upfront group, there were 14 patients with active disease and 4 patients in second CR before transplant. The majority of patients received antithymocyte globulin-based graft-versus-host disease prophylaxis. Median follow-up time was 51 months for both groups. 5-year overall survival (OS) was 54% in the upfront allo-HCT group. While, in the non-upfront group, 5-year OS were 19% (P = 0.013). 5-year progression free survival in the upfront group was higher than that in the non-upfront group (50% versus 20%, P = 0.02). 5-year cumulative incidence relapse rate was significantly higher in non-upfront group (64% vs. 32%, P = 0.006). While, there was no difference in the 5-year non-relapse mortality (NRM) rate (19% versus 16%, P = 0.56). The most common cause of death was disease progression. In multivariable analysis, non-upfront allo-HCT (hazard ratios (HR) 2.14, P = 0.03) and HCT-CI (≥ 2) (HR 6.07, P = 0.002) were identified to be associated with worse OS. Non-upfront allo-HCT and HCT-CI (≥ 2) were also found to be independent risk factors for higher relapse rate. While, haploidentical-HCT was found to be associated with increased NRM. CONCLUSIONS: Our study indicated that allo-HCT remains an important curative treatment for adult patients with T-ALL, especially when it was performed in the upfront setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationRemission InductionHumansAdultMaleFemaleRetrospective StudiesMiddle AgedPrecursor T-Cell Lymphoblastic Leukemia-LymphomaYoung AdultTransplantation, HomologousSurvival RateAgedGraft vs Host DiseaseAdolescentAllograftsLeukemia-Lymphoma, Adult T-CellFollow-Up StudiesDisease-Free Survival

Stichwörter der Autor:innen

Allogeneic stem cell transplantationAntithymocyte globulinCR1T-cell acute lymphoblastic leukemia/lymphomaUpfront

Autor:innen und Institutionen

  • Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, East St 8th, Fengtai District, Beijing, 100071, China.
  • Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, East St 8th, Fengtai District, Beijing, 100071, China. lipingruirui@163.com.
  • Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, East St 8th, Fengtai District, Beijing, 100071, China. daihongrm@163.com.

Förderung

  • Youth Fund of the National Natural Science Foundation of China

Zitieren

APA

Gu, Z., Li, F., Li, M., Wang, L., Lu, N., Jin, X., Wang, L., Gao, C., Dou, L., & Liu, D. (2024). Upfront allogeneic hematopoietic stem cell transplantation for adult T-cell acute lymphoblastic leukemia/lymphoma in first complete remission: a single-center study. Annals of Hematology, 103(7), 2445-2454. https://doi.org/10.1007/s00277-024-05716-w

Vancouver

Gu Z, Li F, Li M, Wang L, Lu N, Jin X, et al. Upfront allogeneic hematopoietic stem cell transplantation for adult T-cell acute lymphoblastic leukemia/lymphoma in first complete remission: a single-center study. Annals of Hematology. 2024;103(7):2445-2454. doi:10.1007/s00277-024-05716-w

BibTeX
@article{Gu2024,
  author = {Gu, Zhenyang and Li, Fei and Li, Meng and Wang, Lu and Lu, Ning and Jin, Xiangshu and Wang, Lili and Gao, Chunji and Dou, Liping and Liu, Daihong},
  title = {Upfront allogeneic hematopoietic stem cell transplantation for adult T-cell acute lymphoblastic leukemia/lymphoma in first complete remission: a single-center study},
  journal = {Annals of Hematology},
  year = {2024},
  volume = {103},
  number = {7},
  pages = {2445--2454},
  doi = {10.1007/s00277-024-05716-w}
}
Kostenlos starten →